Synthesis method of cocilastat chiral diamine intermediate

By performing Boc protection, iodide reaction and Negishi coupling reaction on L-phenylalanol, the synthesis process of cocistat chiral diamine intermediate is simplified, and the cumbersome synthesis route and safety hazards in the prior art are solved. The problem has achieved efficient and low-cost product acquisition.

CN119039150APending Publication Date: 2024-11-29SHAANXI INST OF INT TRADE & COMMERCE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411086301.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing synthesis method of cocilista chiral diamine intermediates has problems such as racemicization of products, complicated synthesis routes, low product yields, high synthesis costs, and safety hazards when using dangerous reagents.

Method used

L-phenylalanol is used to obtain (2R,5R)-1,6-diphenylhex-2,5-diamine hydrochloric acid through Boc protection, iodine reaction, Negishi coupling reaction and Boc removal step. Salt, simplifies the synthesis route, avoids dangerous reagents, and improves product yield and synthesis efficiency.

Benefits of technology

The synthesis of cocistat chiral diamine intermediates with high efficiency, safety and low cost is achieved, which simplifies process conditions, reduces production costs, and avoids the use of dangerous reagents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039150A_ABST
    Figure CN119039150A_ABST
Patent Text Reader

Abstract

The invention relates to a method for synthesizing a cocilastat chiral diamine intermediate, which comprises the following steps: S1, carrying out Boc protection on L-phenylalaninol to obtain [(2S)-1-hydroxy-3-phenylpropyl-2-yl] tert-butyl carbamate; s2, through an iodination reaction, an iodine atom is introduced into [(2S)-1-hydroxy-3-phenylpropyl-2-yl] tert-butyl carbamate, and N-[(2S)-1-iodo-3-phenylpropyl-2-yl] tert-butyl carbamate is obtained; s3, the N-[(2S)-1-iodo-3-phenylpropyl-2-yl] tert-butyl carbamate is subjected to a Negishi coupling reaction, and N-{(2R, 5R)-5-[(t-butyloxycarboryl) amino]-1, 6-diphenylhexane-2-yl} tert-butyl carbamate is obtained, and the N-{(2R, 5R)-5-[(t-butyloxycarboryl) amino]-1, 6-diphenylhexane-2-yl} tert-butyl carbamate is obtained. And S4, the N-{(2R, 5R)-5-[(t-butyloxycarboryl) amino]-1, 6-diphenylhexane-2-yl} carbamic acid tert-butyl ester is subjected to Boc protection removal, and (2R, 5R)-1, 6-diphenylhexane-2, 5-diamine hydrochloride is obtained. The synthesis method is simple in synthesis route, mild in process condition, high in product yield and higher in synthesis efficiency, potential safety hazards are reduced, and the production cost of the cocilastat can be reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and particularly relates to a method for synthesizing a cobicistat chiral diamine intermediate. Background Art

[0002] AIDS, also known as acquired immunodeficiency syndrome, is one of the major infectious diseases that endangers human health and is caused by human immunodeficiency virus (HIV) infection. Due to the drug resistance of a single drug and the high variability of HIV, the treatment of AIDS is currently mainly through a combination of drugs, namely "cocktail therapy". In 2012, the FDA approved Cobicistat (GS-9350) developed by Gilead Pharmaceuticals for marketing in the United States. The trade name of Cobicistat is It is a highly effective and selective human cytochrome P450 3A enzyme inhibitor. Although cobistat itself does not have anti-HIV activity, as an anti-HIV drug enhancer, cobistat can be used in combination with other anti-AIDS drugs to promote or enhance the anti-HIV activity of other drugs. Cobistat can effectively inhibit the activity of cellular P4503A enzymes and reduce the metabolic rate of anti-HIV drugs to achieve the purpose of prolonging the duration of drug action. Cobistat is improved on the structure of the anti-HIV drug Ritonavir and shows higher selectivity and activity.

[0003] See also Figure 1 , Figure 1 This is a schematic diagram of the chemical structure of Cobicistat. The structure of Cobicistat consists of four parts: fragment I, fragment II, fragment III, and fragment IV. Fragment III containing two chiral centers: (2R,5R)-1,6-diphenyl-2,5-hexanediamine is the core skeleton part of the drug molecule. Since it involves the construction and maintenance of chirality, the synthesis is the most difficult.

[0004] The synthesis of chiral diamine skeleton is a key step in the synthesis research of Cobicistat. Currently, there are mainly the following synthetic routes:

[0005] Route 1: See Figure 2 , Figure 2 The present invention provides a schematic diagram of the first synthesis route of a chiral diamine skeleton provided by the prior art. The route uses L-phenylalanine as a raw material to synthesize raw material (1-21) or (1-22), couples (1-21) with (1-22) to obtain an intermediate (1-23), and then undergoes a reduction elimination reaction to obtain an olefin intermediate (1-24). The intermediate undergoes a two-step debenzylation and reduction reaction to obtain a key intermediate (1-26) of a chiral diamine skeleton.

[0006] Route 2: See Figure 3 , Figure 3 The present invention is a schematic diagram of a second synthesis route of a chiral diamine skeleton provided by the prior art. The route first involves Cbz protection of L-phenylalaninol (1-27) to obtain an intermediate (1-28), followed by a chlorination reaction to obtain an intermediate (1-29), followed by coupling to obtain a geminal diol intermediate (1-30), followed by cyclization with a thiolation reagent (CSDI) to obtain (1-31), followed by an elimination reaction to obtain an olefin intermediate (1-32), and finally reduction and deprotection to obtain a key intermediate (1-26).

[0007] Route 3: See Figure 4 , Figure 4 A schematic diagram of the third synthesis route of the chiral diamine skeleton provided by the prior art, wherein L-phenylalaninol (1-27) or (1-23) is used as a raw material, and N-heterocyclopropane intermediate (1-35) can be obtained through different steps, and then, an intermolecular coupling reaction occurs under the action of LiTMP to obtain an intermediate (1-36), and then a two-step deprotection and reduction reaction is performed to obtain a key intermediate (1-26).

[0008] Route 4: See Figure 5 , Figure 5 A schematic diagram of the fourth synthesis route of the chiral diamine skeleton provided by the prior art, in which diethyl adipate (1-38) is subjected to two nucleophilic substitution reactions to achieve benzylation to obtain an intermediate (1-39), which is then subjected to hydrolysis and Curtius rearrangement reactions in sequence to obtain a racemic product (1-41), which can finally be subjected to chiral resolution to obtain a mixture of two configurations, S,S and R,R.

[0009] Route 5: See Figure 6 , Figure 6 A schematic diagram of the fourth synthetic route of the chiral diamine skeleton provided in the prior art. Based on route 4, compound 1-40 is chlorinated and then reacted with ammonia to obtain an amide intermediate (1-42). The amide intermediate is subjected to Hofmann degradation to obtain a racemic product (1-41), and finally subjected to chiral resolution to obtain the target intermediate (1-26).

[0010] However, the synthesis method of route 1 is relatively complicated, and dangerous reagents such as n-butyl lithium and metallic sodium are used in the reaction, which poses a safety hazard. Although route 2 has a shorter step, it uses precious metal catalysts and some reagents that are more harmful to the environment. Route 3 uses expensive reagents, which increases production costs and produces some by-products that cannot be recycled, and the overall efficiency is not high. The biggest drawback of route 4 is that the product obtained is a mixture of two configurations, rather than a single configuration product. Route 5 obtains a single configuration product through chiral splitting, but the splitting will result in the waste of the other isomer, making the overall synthesis efficiency low.

[0011] Therefore, the synthesis of chiral diamine skeletons has problems such as product racemization, the need for chiral separation, complicated synthesis routes, low product yields, high synthesis costs, the use of dangerous reagents such as n-butyl lithium, metallic sodium, palladium carbon, and greater safety hazards. Summary of the invention

[0012] In order to solve the above problems existing in the prior art, the present invention provides a method for synthesizing a chiral diamine intermediate of cobicistat. The technical problem to be solved by the present invention is achieved by the following technical solution:

[0013] The embodiment of the present invention provides a method for synthesizing a cobicistat chiral diamine intermediate, comprising the steps of:

[0014] S1, performing Boc protection on L-phenylalaninol to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate;

[0015] S2, introducing an iodine atom into the [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester by iodination reaction to obtain N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester;

[0016] S3, subjecting the N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester to a Negishi coupling reaction to obtain N-{(2R,5R)-5-[(tert-butyloxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester;

[0017] S4, removing the Boc protection from the tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride.

[0018] In one embodiment of the present invention, step S1 comprises:

[0019] L-phenylalaninol and tert-butyloxycarbonyl compound are added to dichloromethane and stirred evenly, and then triethylamine is added dropwise to carry out Boc amino protection reaction; after the reaction is completed, the reaction solution is washed, and the organic phase obtained by washing is dried to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate.

[0020] In one embodiment of the present invention, step S2 comprises:

[0021] Triphenyl phosphate and imidazole are added to dichloromethane and stirred evenly, and then elemental iodine is added to react in the dark, and then a dichloromethane solution of [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester is added dropwise to carry out iodination reaction; after the reaction is completed, the reaction solution is filtered under reduced pressure, the filtrate is concentrated under reduced pressure, and the crude product is separated and purified to obtain N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester.

[0022] In one embodiment of the present invention, step S3 includes:

[0023] Under nitrogen protection, tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate, a zinc-copper coupling agent, a catalyst, and tetramethylethylenediamine are added to an organic solvent to carry out a Negishi coupling reaction. After the reaction, the reaction solution is diluted, extracted, the organic phase is washed, dried, concentrated under reduced pressure, and the crude product is separated and purified to obtain tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate.

[0024] In one embodiment of the present invention, the organic solvent includes one or two of 1,4-dioxane, N,N-dimethylformamide and acetonitrile.

[0025] In one embodiment of the present invention, the mass percentage of Cu in the zinc-copper coupling agent is 1-10%;

[0026] The molar ratio of the zinc-copper coupling agent to the N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester is 0.1:1 to 0.5:1.

[0027] In one embodiment of the present invention, the catalyst comprises Ni(dppf)Cl 2 、Pd(dppf)Cl 2 、Pd(PPh 3 ) 4 、Pd(Amphos) 2 Cl 2 One or more of .

[0028] In one embodiment of the present invention, the molar ratio of the catalyst to the tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate is 0.01:1 to 0.06:1.

[0029] In one embodiment of the present invention, the reaction temperature of the Negishi coupling reaction is 0-65° C., and the reaction time is 8-16 h.

[0030] In one embodiment of the present invention, step S4 includes:

[0031] The tert-butyl N-{(2R,5R)-5-[(tert-butyloxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate is added to a hydrogen chloride ethyl acetate solution to carry out a Boc protection removal reaction. After the reaction is completed, the mixture is filtered under reduced pressure, and then slurried in ethyl acetate and filtered under reduced pressure again to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] The synthesis method of the invention uses L-phenylalaninol as a raw material, and sequentially undergoes Boc protection, iodination reaction, Negishi coupling reaction, and Boc removal reaction to finally obtain the target compound (2R, 5R)-1,6-diphenylhexane-2,5-diamine hydrochloride. The synthesis route is simple, the process conditions are mild, the product yield is high, the synthesis efficiency is higher, the use of hazardous reagents and high-cost reagents is avoided, the safety hazards are reduced, and the production cost of cocistat can be reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 is a schematic diagram of the chemical structure of cobicistat;

[0035] Figure 2 A schematic diagram of the first synthesis route of the chiral diamine skeleton provided in the prior art;

[0036] Figure 3 A schematic diagram of a second synthesis route of a chiral diamine skeleton provided in the prior art;

[0037] Figure 4 A schematic diagram of the third synthesis route of the chiral diamine skeleton provided in the prior art;

[0038] Figure 5 A schematic diagram of the fourth synthesis route of the chiral diamine skeleton provided in the prior art;

[0039] Figure 6 A schematic diagram of the fourth synthesis route of the chiral diamine skeleton provided in the prior art;

[0040] Figure 7 A schematic flow chart of a method for synthesizing a cobicistat chiral diamine intermediate provided in an embodiment of the present invention;

[0041] Figure 8 A schematic diagram of the synthesis route of a cilastat chiral diamine intermediate provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0042] The present invention is further described in detail below with reference to specific embodiments, but the embodiments of the present invention are not limited thereto.

[0043] Embodiment 1

[0044] See also Figure 7 and Figure 8 , Figure 7 A schematic flow chart of a method for synthesizing a cobicistat chiral diamine intermediate provided in an embodiment of the present invention, Figure 8 A schematic diagram of a synthesis route of a cilastat chiral diamine intermediate provided in an embodiment of the present invention. The synthesis method of the cilastat chiral diamine intermediate comprises the steps of:

[0045] S1. Perform Boc protection on L-phenylalaninol 2 to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate 3.

[0046] Specifically, L-phenylalaninol 2 and di-tert-butyl dicarbonate (Boc) 2 O was added into dichloromethane and stirred evenly, and then triethylamine was added dropwise to carry out Boc amino protection reaction, the reaction temperature was 0°C, and the reaction time was 2.5 h. After the reaction was completed, the reaction solution was washed, and the organic phase obtained by washing was dried to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate 3, which was an off-white solid.

[0047] Specifically, L-phenylalaninol, di-tert-butyl dicarbonate (Boc) 2 The molar ratio of L-phenylalaninol, di-tert-butyl dicarbonate and triethylamine is 132:139:278, and the corresponding mass ratio of L-phenylalaninol, di-tert-butyl dicarbonate and triethylamine is 20.0:30.3:28.1. Exemplarily, the molar amount of L-phenylalaninol is 132mmol, corresponding to a mass of 20.0g; the molar amount of di-tert-butyl dicarbonate is 139mmol, corresponding to a mass of 30.3g; the molar amount of triethylamine is 278mmol, corresponding to a mass of 28.1g.

[0048] S2. By iodination reaction, an iodine atom is introduced into tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate 3 to obtain tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4.

[0049] Specifically, triphenyl phosphate TPP and imidazole are added to dichloromethane and stirred evenly, and then elemental iodine is added for light-proof reaction, and then a dichloromethane solution of [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3 is added dropwise for iodination reaction, the reaction temperature is 0°C, and the reaction time is 1h; after the reaction is completed, the reaction solution is filtered under reduced pressure, the filtrate is concentrated under reduced pressure, and the crude product is separated and purified to obtain N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 4, and N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 4 is a white solid.

[0050] Specifically, the molar ratio of triphenyl phosphate TTP, imidazole, elemental iodine, and [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3 is 120:120:120:110, and correspondingly, the mass ratio of triphenyl phosphate TTP, imidazole, elemental iodine, and [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3 is 39.2:8.2:30.5:27.6. Exemplarily, the molar amount of triphenyl phosphate TTP is 120mmol, and the corresponding mass is 39.2g; the molar amount of imidazole is 120mmol, and the corresponding mass is 8.2g; the molar amount of elemental iodine is 120mmol, and the corresponding mass is 30.5g, and the molar amount of [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3 is 110mmol, and the corresponding mass is 27.6g.

[0051] S3. Subject tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4 to a Negishi coupling reaction to obtain tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate 5.

[0052] Specifically, under nitrogen protection, tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4, zinc-copper coupling agent, catalyst, and tetramethylethylenediamine TMEDA are added to an organic solvent to carry out Negishi coupling reaction. After the reaction, the reaction solution is diluted, extracted, the organic phase is washed, dried, concentrated under reduced pressure, and the crude product is separated and purified to obtain tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate 5. tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate 5 is a light yellow solid.

[0053] Specifically, the organic solvent includes one or two of 1,4-dioxane, N,N-dimethylformamide and acetonitrile. Exemplarily, the organic solvent is N,N-dimethylformamide, or a mixture of N,N-dimethylformamide and acetonitrile.

[0054] Specifically, the mass percentage of Cu in the zinc-copper coupling agent is 1-10%. For example, the mass percentage of Cu in the zinc-copper coupling agent is 3%, i.e., Zn (3% Cu). The molar ratio of the zinc-copper coupling agent to tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4 is 0.1:1 to 0.5:1, i.e., the amount of the zinc-copper coupling agent is: n (zinc-copper coupling agent): n (intermediate 4) = 0.1:1 to 0.5:1, wherein the intermediate 4 is tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate.

[0055] Specifically, the catalyst may be a Pd complex or a Ni complex. Exemplary catalysts include (1,1'-bis(diphenylphosphino)ferrocene) nickel dichloride (Ni(dppf)Cl 2 ), bis(triphenylphosphine)palladium chloride (Pd(PPh 3 ) 2 Cl 2 ), tetrakis(triphenylphosphine)palladium(Pd(PPh 3 ) 4 ), bis(di-tert-butyl-4-dimethylaminophenylphosphine)palladium chloride (Pd(Amphos) 2 Cl 2 ). The molar ratio of the catalyst to tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4 is 0.01:1 to 0.06:1, that is, the amount of the catalyst is n (catalyst): n (compound 4) = 0.01:1 to 0.06:1.

[0056] Specifically, tetramethylethylenediamine is used as a weak base to adjust the pH value of the solution. The molar ratio of tetramethylethylenediamine to tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4 is 1:6 to 1:8. Exemplarily, the molar ratio of tetramethylethylenediamine to tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4 is 1:7, that is, n(tetramethylethylenediamine):n(compound 4)=0.01:1 to 0.06:1.

[0057] Exemplarily, under nitrogen protection, intermediate 4, Zn (3% Cu), (Amphos) 2 PdCl 2, TMEDA was added to N,N-dimethylformamide solvent, the amount of zinc copper coupling agent and intermediate 4 was n(Zn(3%Cu)):n(intermediate 4)=0.3:1, and the fixed catalyst was Pd(Amphos) 2 Cl 2 、Catalyst dosage n(Pd(Amphos) 2 Cl 2 ):n(intermediate 4)=0.05:1, reaction temperature is 25°C, reaction time is 12h. After the reaction is completed, saturated brine is added to dilute, and then ethyl acetate is added to extract. The organic phase is washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product is separated and purified by silica gel column chromatography (the eluent is a mixture of ethyl acetate and petroleum ether, the volume ratio is 1:2) to obtain a light yellow solid.

[0058] S4. Remove the Boc protection from tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate 5 to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1.

[0059] Specifically, tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate 5 is added to a hydrogen chloride ethyl acetate solution to carry out a Boc protection removal reaction. After the reaction is completed, the mixture is filtered under reduced pressure, and then slurried in ethyl acetate and filtered under reduced pressure again to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1. (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1 is a light yellow solid.

[0060] In this example, L-phenylalaninol 2 is used as a raw material, and undergoes Boc protection to obtain an intermediate [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3, which is then subjected to an iodine substitution reaction to obtain an intermediate N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 4, which is then subjected to a Negishi coupling reaction to obtain an intermediate N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester 5. Finally, the intermediate 5 is deprotected from Boc to obtain the target compound (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1. This embodiment provides a simple and efficient synthesis method for preparing the cobicistat intermediate (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1, which has a simple synthesis route, mild process conditions, high product yield, higher synthesis efficiency, avoids the use of hazardous reagents and high-cost reagents, reduces safety hazards, can reduce the production cost of cobicistat, and is of great significance for its industrial application.

[0061] Embodiment 2

[0062] Based on Example 1, this example further illustrates the synthesis method of the chiral diamine intermediate of cobicistat through the following examples.

[0063] Example 1

[0064] See also Figure 8 The synthesis method of the cobicistat chiral diamine intermediate comprises the steps of:

[0065] S1. Perform Boc protection on L-phenylalaninol 2 to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate 3.

[0066] At 0°C, 20.0 g (132 mmol) of L-phenylalaninol 2 and 30.3 g (139 mmol) (Boc 2 O was added to dichloromethane (400 mL), stirred evenly, and then 28.1 g (278 mmol) of triethylamine was slowly added dropwise, and the reaction was carried out at 0°C for 2.5 h. After the reaction was completed by TLC monitoring, it was washed with water (400 mL), saturated sodium bicarbonate solution (400 mL), and saturated brine (400 mL) in sequence. Finally, the organic phase was dried over anhydrous sodium sulfate to obtain 33.0 g of gray-white solid, i.e., the intermediate [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 3, with a yield of 99%. ESI-MS, m / z: 152.1 [M-Boc+1] + .

[0067] S2. By iodination reaction, an iodine atom is introduced into the tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate 3 to obtain tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate 4.

[0068] 39.2 g (120 mmol) of TPP and 8.2 g (120 mmol) of imidazole were added to dichloromethane (350 mL), stirred evenly, and then 30.5 g (120 mmol) of elemental iodine was added at 0°C. After the reaction was protected from light for 1.5 h, 27.6 g (110 mmol) of dichloromethane solution (350 mL) of intermediate 3 was added dropwise at 0°C, and the reaction was continued at 0°C for 1 h. After the reaction was completed by TLC monitoring, the filtrate was filtered under reduced pressure, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (the eluent was a mixture of ethyl acetate and petroleum ether, with a volume ratio of 1:2), and 24.2 g of white solid, namely, intermediate N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 4, was obtained, with a yield of 61%. ESI-MS, m / z: 261.9 [M-Boc+1] + .

[0069] S3. Subject the N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester 4 to a Negishi coupling reaction to obtain N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester 5.

[0070] According to the fixed zinc-copper coupling agent dosage of n(Zn(3%Cu)):n(intermediate 4)=0.3:1, Pd(Amphos) 2 Cl 2 is the catalyst, the catalyst dosage n(Pd(Amphos) 2 Cl 2 ):n(intermediate 4)=0.05:1, under nitrogen protection, 22.0g (61mmol) of intermediate 4, 12.0g (18.3mmol) of Zn (3% Cu), 2.20g (3.0mmol) (Amphos 2 PdCl 2 and 1.1 g (9.1 mmol) TMEDA were added to N, N-dimethylformamide (60 mL) in sequence, and reacted at room temperature (25 ° C) for 12 h. After the reaction was completed by TLC monitoring, saturated brine (100 mL) was added for dilution, and then ethyl acetate was added for extraction (3×100 mL). The organic phase was washed with saturated brine (3×200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (the eluent was a mixture of ethyl acetate and petroleum ether, with a volume ratio of 1:2) to obtain 5.2 g of light yellow solid, namely the intermediate N-{(2R,5R)-5-[(tert-butyloxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester 5, with a yield of 47%. ESI-MS, m / z: 369.1 [M-Boc+1] + .

[0071] S4, removing the Boc protection of the N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester 5 to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1.

[0072] 2.6 g (5.6 mmol) of intermediate 5 was added to 2 mol / L hydrogen chloride ethyl acetate solution (25 mL), and the reaction was carried out at room temperature for 2 h. After the reaction was completed as monitored by TLC, the reaction was filtered off under reduced pressure to obtain a yellow solid. The solid was then slurried in ethyl acetate and filtered off under reduced pressure to obtain 1.9 g of a light yellow solid, i.e., the target product (2R, 5R)-1,6-diphenylhexane-2,5-diamine hydrochloride 1, with a yield of 95%. 1 H NMR (400 MHz, DMSO-d6 )δ:8.35(brs,6H),7.34-7.24(m,10H),3.28-3.20(m,2H),2.98(dd,J=14.0,6 .4Hz,2H),2.78(dd,J=14.0,6.8Hz,2H),1.76-1.70(m,2H),1.62-1.57(m,2H); 13 CNMR (100MHz, DMSO-d 6 )δ:136.5,129.4,128.5,126.7,51.8,37.9,26.9. ESI-MS,m / z:268.0[M+H] + .

[0073] The target product (1) 1 H NMR data were analyzed: the brs peak at δ8.35 was integrated for 6H and was attributed to two primary amines and two molecules of hydrochloride; the multiple peaks at δ7.34-7.24 were integrated for a total of 10H and were all attributed to Ar-H on the two benzene rings; the multiple peaks at δ3.28-3.20 were integrated for a total of 2H and were attributed to the methine connected to the primary amine; the dd peaks at δ2.98 and 2.78 were integrated for 2H and the coupling constants were consistent, and were attributed to two benzylic methylene signal peaks; the multiple peaks at δ1.76-1.70 and δ1.62-1.57 were integrated for a total of 4H and were attributed to two methylene signal peaks. 13 C NMR data analysis: δ136.5, 129.4, 128.5, 126.7 are attributed to the benzene ring carbon signal peaks; δ51.8 is attributed to the methine carbon signal peak connected to the primary amine; δ37.9 is attributed to two benzyl carbon signal peaks; δ26.9 is attributed to two methylene carbon signal peaks. 1 HNMR, 13 C NMR analysis combined with ESI-MS information can finally prove that the structure of product 1 is correct.

[0074] Example 2

[0075] In the method for synthesizing the chiral diamine intermediate of cobicistat provided in this example, the N,N-dimethylformamide solvent in step S3 of example 1 is replaced with 1,4-dioxane, acetonitrile, tetrahydrofuran and water in sequence, and the other conditions remain the same.

[0076] Please refer to Table 1, which shows the effect of different solvents on the yield of intermediate 5. In Table 1, “ / ” represents a trace amount of product, and the yield was calculated without separation and purification.

[0077] Table 1 Effect of different solvents on the yield of intermediate 5

[0078]

[0079]

[0080] As can be seen from Table 1, almost no product is generated in tetrahydrofuran and water, but the reaction can be carried out in the other three solvents. Among them, the yield of compound 5 is as high as 47% in N,N-dimethylformamide. Therefore, N,N-dimethylformamide, 1,4-dioxane, and acetonitrile can be selected as the reaction solvent, and N,N-dimethylformamide is preferred as the reaction solvent.

[0081] Example 3

[0082] The method for synthesizing the chiral diamine intermediate of cobicistat provided in this example replaces the amount of zinc-copper coupling agent and intermediate 4 n(Zn(3%Cu)):n(intermediate 4)=0.3:1 in step S3 of Example 1 with 0.1:1, 0.2:1, 0.4:1, and 0.5:1 respectively, and the other conditions remain the same as in Example 1.

[0083] Please refer to Table 2, which shows the effect of different zinc-copper coupling agent dosages on the yield of intermediate 5.

[0084] Table 2 Effect of different zinc-copper coupling agent dosage on the yield of intermediate 5

[0085] Serial number n(Zn):n(Intermediate 4) Yield / % 1 0.1:1 23 2 0.2:1 39 3 0.3:1 47 4 0.4:1 47 5 0.5:1 45

[0086] As can be seen from Table 2, when the dosage of zinc-copper coupling agent is n(Zn):n(intermediate 4)=0.1:1, the yield of intermediate 5 is 23%. When the dosage is increased to n(Zn):n(intermediate 4)=0.1:1, the yield of compound 5 is significantly increased to 47%, while the yield of compound 5 does not change significantly when the dosage of zinc-copper coupling agent is further increased, so preferably, the dosage of zinc-copper coupling agent is n(Zn):n(intermediate 4)=0.3:1.

[0087] Example 4

[0088] This example provides a method for synthesizing a chiral diamine intermediate of cobicistat, wherein the catalyst Pd(Amphos) in step S3 of example 1 is 2 Cl 2 The catalysts and their amounts are replaced in turn with the catalysts and their amounts shown in Table 3, and the other conditions remain the same as in Example 1.

[0089] Please refer to Table 3, which shows the effects of different catalysts and their dosages on the yield of intermediate 5, wherein “ / ” represents a trace amount of product and the yield was calculated without separation and purification.

[0090] Table 3 Effect of catalyst type and dosage on the yield of intermediate 5

[0091] Serial number Catalyst type n(catalyst):n(intermediate 4) Yield / % 1 <![CDATA[Ni(PPh 3 ) 2 Cl 2 ]]> 0.05:1 / 2 <![CDATA[Ni(dppf)Cl 2 ]]> 0.05:1 36 3 <![CDATA[Pd(dppf)Cl 2 ]]> 0.05:1 27 4 <![CDATA[Pd(PPh 3 ) 2 Cl 2 ]]> 0.05:1 / 5 <![CDATA[Pd(PPh 3 ) 4 ]]> 0.05:1 25 6 <![CDATA[Pd(Amphos) 2 Cl 2 ]]> 0.05:1 47 7 <![CDATA[Pd(Amphos) 2 Cl 2 ]]> 0.06:1 46 8 <![CDATA[Pd(Amphos) 2 Cl 2 ]]> 0.04:1 42

[0092] In Table 3, the catalyst dosage n(catalyst):n(intermediate 4)=0.05:1 was first fixed, and then 6 catalysts were screened and found that: 3 ) 2 Cl 2 and Pd(dppf)Cl 2 Almost no product was generated under the action of two catalysts, but it could be carried out under the action of the other four catalysts. 2 Cl 2 Under catalysis, the yield of intermediate 5 reached up to 47%. 2 Cl 2 It was found that when Pd(Amphos) 2 Cl 2 The dosage is n(Pd(Amphos) 2 Cl 2 ):n(Intermediate 4) increased from 0.05:1 to 0.01:1, the yield of Intermediate 5 did not increase, but when n(Pd(Amphos) 2 Cl 2 ):n(intermediate 4) decreased to 0.04:1, the yield of intermediate 5 began to decrease, so it is preferred that the catalyst show Pd(Amphos) 2 Cl 2 , the dosage is n(Pd(Amphos) 2 Cl 2 ):n(intermediate 4)=0.05:1.

[0093] Example 5

[0094] In the method for synthesizing the chiral diamine intermediate of cobicistat provided in this example, the reaction temperature and reaction time of the Negishi coupling reaction in step S3 of example 1 are replaced with the reaction temperature and reaction time shown in table 4 in sequence, and the other conditions remain the same as those in example 1.

[0095] Please refer to Table 4, which shows the effects of reaction temperature and time on the yield of intermediate 5.

[0096] Table 4 Effect of reaction temperature and time on the yield of intermediate 5

[0097] Serial number Reaction temperature / (℃) Reaction time / (h) Yield / (%) 1 0 12 31 2 25 12 47 3 45 12 43 4 65 12 35 4 25 14 47 5 25 16 46 6 25 10 43 7 25 8 38

[0098] As shown in Table 4, the reaction time was first fixed at 12 h, and the temperature was examined. It was found that when the reaction temperature was 0 ° C, the product yield was only 31%. When the reaction temperature was raised to 25 ° C, the yield of intermediate 5 reached 47%, but when the reaction temperature was further increased, the product yield began to decrease, so the preferred reaction temperature was 25 ° C; then the reaction time was examined, and it was found that when the reaction time was extended to 14 h and 16 h, the yield of intermediate 5 did not change significantly, but when the reaction time was shortened, the yield of intermediate 5 began to decrease, so the preferred reaction time was 12 h.

[0099] In this example, L-phenylalaninol is used as a raw material, and four steps of Boc protection, iodine substitution, Negishi coupling and de-Boc protection are sequentially performed to synthesize (2R, 5R)-1,6-diphenylhexane-2,5-diamine hydrochloride. The process conditions are milder, the synthesis efficiency is higher, and the production cost of cocistat can be reduced.

[0100] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.

Claims

1. A method for synthesizing a chiral diamine intermediate of cobicistat, characterized in that: Includes steps: S1, performing Boc protection on L-phenylalaninol to obtain tert-butyl [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamate; S2, introducing an iodine atom into the [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester by iodination reaction to obtain N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester; S3, subjecting the N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester to a Negishi coupling reaction to obtain N-{(2R,5R)-5-[(tert-butyloxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamic acid tert-butyl ester; S4, removing the Boc protection from the tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride.

2. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 1, characterized in that: Step S1 includes: L-phenylalaninol and di-tert-butyl dicarbonate are added to dichloromethane and stirred evenly, and then triethylamine is added dropwise to carry out Boc amino protection reaction; after the reaction is completed, the reaction solution is washed, and the organic phase obtained by washing is dried to obtain [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester.

3. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 1, characterized in that: Step S2 includes: Triphenyl phosphate and imidazole are added to dichloromethane and stirred evenly, and then elemental iodine is added to react in the dark, and then a dichloromethane solution of [(2S)-1-hydroxy-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester is added dropwise to carry out iodination reaction; after the reaction is completed, the reaction solution is filtered under reduced pressure, the filtrate is concentrated under reduced pressure, and the crude product is separated and purified to obtain N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester.

4. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 1, characterized in that: Step S3 includes: Under nitrogen protection, tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate, a zinc-copper coupling agent, a catalyst, and tetramethylethylenediamine are added to an organic solvent to carry out a Negishi coupling reaction. After the reaction, the reaction solution is diluted, extracted, the organic phase is washed, dried, concentrated under reduced pressure, and the crude product is separated and purified to obtain tert-butyl N-{(2R,5R)-5-[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate.

5. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 4, characterized in that: The organic solvent includes one or two of 1,4-dioxane, N,N-dimethylformamide and acetonitrile.

6. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 4, characterized in that: The mass percentage of Cu in the zinc-copper coupling agent is 1-10%; The molar ratio of the zinc-copper coupling agent to the N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamic acid tert-butyl ester is 0.1:1 to 0.5:

1.

7. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 4, characterized in that: The catalyst includes one or more of Ni(dppf)Cl2, Pd(dppf)Cl2, Pd(PPh3)4, and Pd(Amphos)2Cl2.

8. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 4, characterized in that: The molar ratio of the catalyst to the tert-butyl N-[(2S)-1-iodo-3-phenylpropyl-2-yl]carbamate is 0.01:1 to 0.06:

1.

9. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 4, characterized in that: The reaction temperature of the Negishi coupling reaction is 0-65° C., and the reaction time is 8-16 hours.

10. The method for synthesizing the chiral diamine intermediate of cobicistat according to claim 1, characterized in that: Step S4 includes: The tert-butyl N-{(2R,5R)-5-[(tert-butyloxycarbonyl)amino]-1,6-diphenylhexane-2-yl}carbamate is added to a hydrogen chloride ethyl acetate solution to carry out a Boc protection removal reaction. After the reaction is completed, the mixture is filtered under reduced pressure, and then slurried in ethyl acetate and filtered under reduced pressure again to obtain (2R,5R)-1,6-diphenylhexane-2,5-diamine hydrochloride.